Prestige Consumer Healthcare AI Stock Analysis
Want to see PBH full AI Analyst Report?
Prestige Consumer Healthcare (PBH) AI Stock Analysis
Prestige Consumer Healthcare
(NYSE:PBH)
PBH scores as moderately attractive mainly due to solid underlying profitability and cash generation, supported by reasonable valuation. The score is held back by weak technicals (price below key moving averages) and earnings-call risks tied to Clear Eyes supply volatility, higher interest expense, and elevated leverage despite generally positive operating/acquisition momentum.
Prestige Consumer Healthcare (PBH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.29B
- Dividend Yield
- ―
- Average Volume (3M)
- 573.57K
- Price to Earnings (P/E)
- 14.9
- Beta (1Y)
- 0.44
- Revenue Growth
- 5.10%
- EPS Growth
- -19.73%
- Country
- US
- Employees
- 890
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Prestige Consumer Healthcare Business Overview & Revenue Model
Company Description
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's...
How the Company Makes Money
Prestige Consumer Healthcare primarily makes money by selling branded OTC consumer healthcare products to retailers and distributors, recognizing revenue when control of products transfers under its customer arrangements. Its key revenue streams are...
Prestige Consumer Healthcare Earnings Call Summary
The call was predominantly positive: the company exceeded second-quarter sales and earnings expectations, reported strong profitability, maintained healthy base-business consumption trends, and described both acquisitions as performing well. eCommerce, key GI brands, international brands, and long-term Clear Eyes opportunities were also highlighted. The principal negative was Clear Eyes production volatility, which reduced the full-year outlook and limited near-term sales, while working-capital timing and higher interest expense pressured cash flow and EPS. Overall, the positive operating and acquisition trends significantly outweighed the identified challenges.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal 2027, the company now expects full-year revenue of $1.28 billion-$1.29 billion, which equates to about 2% organic growth, excluding Clear Eyes, including approximately $190 million of revenue from Breathe Right and LaCorium; Clear Eyes sales are now forecast at less than $20 million for the full year, with limited improvement in the second half expected. Q3 revenue is expected to be approximately $328 million, with organic revenue decreasing year-over-year, and adjusted diluted EPS is expected to be $4.48-$4.55 for the full year and $1.05 for Q3. The company expects adjusted gross margin of just over 57% for the full year and just over 58% gross margin for the remainder of the year, an A&M rate of approximately 14.5% of sales, adjusted G&A of approximately 10% as a percent of sales, interest expense of approximately $104 million, amortization expense of $32 million, adjusted free cash flow of $265 million or more, and a year-end leverage ratio of approximately four times; long-term CapEx is expected to be 1%-3% of sales, with the company taking a look at $26 million for this year.
Prestige Consumer Healthcare Financial Statement Overview
Summary
Financials are solid overall: strong profitability and cash generation (healthy margins and robust free cash flow with good conversion), offset by modest longer-term revenue growth, recent softening in free-cash-flow growth, and some uncertainty/volatility in leverage and prior-period results.
Income Statement
76PositiveBalance Sheet
70PositiveCash Flow
73Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.17B | 1.09B | 1.14B | 1.13B | 1.13B | 1.09B |
| Gross Profit | 606.96M | 574.64M | 634.46M | 624.45M | 625.29M | 620.65M |
| EBITDA | 315.31M | 331.11M | 361.99M | 373.86M | 7.87M | 358.84M |
| Net Income | 155.10M | 190.30M | 214.60M | 209.34M | -82.31M | 205.38M |
Balance Sheet | ||||||
| Total Assets | 4.72B | 3.55B | 3.40B | 3.32B | 3.35B | 3.67B |
| Cash, Cash Equivalents and Short-Term Investments | 46.52M | 63.87M | 97.88M | 46.47M | 58.49M | 27.18M |
| Total Debt | 2.12B | 1.05B | 1.04B | 1.14B | 1.37B | 1.51B |
| Total Liabilities | 2.78B | 1.66B | 1.57B | 1.66B | 1.91B | 2.09B |
| Stockholders Equity | 1.94B | 1.89B | 1.83B | 1.66B | 1.45B | 1.58B |
Cash Flow | ||||||
| Free Cash Flow | 214.22M | 246.45M | 243.29M | 239.38M | 221.93M | 250.28M |
| Operating Cash Flow | 229.78M | 257.63M | 251.51M | 248.93M | 229.72M | 259.92M |
| Investing Cash Flow | -1.33B | -136.84M | -17.45M | -20.11M | -11.58M | -256.51M |
| Financing Cash Flow | 1.03B | -156.06M | -182.07M | -241.01M | -185.85M | -7.57M |
Prestige Consumer Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBH, the sentiment is Positive. The current price of 48.22 is above the 20-day moving average (MA) of 47.34, above the 50-day MA of 47.29, and below the 200-day MA of 52.98, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 54.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBH.
Prestige Consumer Healthcare Risk Analysis
Prestige Consumer Healthcare disclosed 25 risk factors in its most recent earnings report. Prestige Consumer Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPrestige Consumer Healthcare Peers Comparison
Overall Rating
PBH65Neutral
SCYX53Neutral
BFRI43Neutral
COSM38Underperform
NSRX29Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $2.29B | 14.87 | 8.19% | ― | 5.10% | -19.73% | |
| 53Neutral | $28.37M | -2.44 | -18.65% | ― | 543.96% | 72.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $10.65M | -1.48 | -110.30% | ― | 29.85% | 78.56% | |
| 38Underperform | $14.34M | -0.22 | -118.89% | ― | 33.82% | 34.05% | |
| 29Underperform | $30.57M | -2.54 | -158.83% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare | 48.22 | -10.27 | -17.56% | |
| SCYX | SCYNEXIS Inc | 2.85 | -1.87 | -39.62% | |
| COSM | Cosmos Holdings | 2.85 | -10.13 | -78.05% | |
| BFRI | Biofrontera, Inc. | 0.59 | -0.22 | -26.70% | |
| NSRX | Nasus Pharma Ltd. | 2.61 | -4.39 | -62.71% | |
| CUVL | Clinuvel Pharmaceuticals Limited Sponsored ADR | 4.90 | -2.10 | -30.03% |
Prestige Consumer Healthcare Corporate Events
Prestige Consumer Healthcare Reports Fiscal 2027 Second-Quarter Results
PositivePrestige Consumer Healthcare, an over-the-counter healthcare company serving North American and international markets, reported fiscal 2027 second-quarter and first-half results on November 5, 2026. Its portfolio included consumer health brands such...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
